Family Caregiver Palliative Care Intervention in Supporting Caregivers of Patients With Stage II-IV Gastrointestinal, Gynecologic, Urologic and Lung Cancers

NCT ID: NCT01846520

Last Updated: 2020-01-23

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

200 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-10-31

Study Completion Date

2019-05-23

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This randomized clinical trial studies the Family Caregiver Palliative Care Intervention in supporting caregivers of patients with stage II-IV gastrointestinal, gynecologic, urologic and lung cancers. Education and telephone counseling may reduce stress and improve the well-being and quality of life of caregivers of cancer patients.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

PRIMARY OBJECTIVES: I. Test the effects of the Family Caregiver Palliative Care Intervention (FCPCI) on family caregivers of patients with gastrointestinal, gynecologic, urologic and lung cancers in the experimental group on caregiver burden and caregiving skills preparedness as compared to family caregivers in the control group.

II. Test the effects of the FCPCI on family caregivers of patients with gastrointestinal, gynecologic, urologic and lung cancers in the experimental group on quality of life (QOL) and psychological distress as compared to family caregivers in the control group.

SECONDARY OBJECTIVES: I. Describe family caregivers' self-care behavior, comparing the experimental and control groups.

II. Describe family caregivers' resource use, comparing the experimental and control groups.

III. Identify subgroups of family caregivers who benefit most from the FCPCI in relation to sociodemographic, health status, and patient characteristics.

IV. Describe family caregivers' satisfaction with the FCPCI.

V. Describe caregiver out-of-pocket costs and the cost of the intervention.

OUTLINE: Participants are randomized to 1 of 2 arms.

ARM I: Participants receive FCPCI with an advanced practice nurse (APN), comprising 4 home education sessions once weekly followed by 4 telephone support sessions for 30 minutes once monthly and 24 hour telephone support available for 6 months.

ARM II: Participants receive usual care

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy Subject Localized Transitional Cell Cancer of the Renal Pelvis and Ureter Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter Psychosocial Effects of Cancer and Its Treatment Recurrent Bladder Cancer Recurrent Cervical Cancer Recurrent Colon Cancer Recurrent Gastric Cancer Recurrent Ovarian Epithelial Cancer Recurrent Ovarian Germ Cell Tumor Recurrent Pancreatic Cancer Recurrent Rectal Cancer Recurrent Renal Cell Cancer Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter Recurrent Urethral Cancer Recurrent Uterine Sarcoma Regional Transitional Cell Cancer of the Renal Pelvis and Ureter Stage II Bladder Cancer Stage II Renal Cell Cancer Stage II Urethral Cancer Stage IIA Cervical Cancer Stage IIA Colon Cancer Stage IIA Gastric Cancer Stage IIA Ovarian Epithelial Cancer Stage IIA Ovarian Germ Cell Tumor Stage IIA Pancreatic Cancer Stage IIA Rectal Cancer Stage IIA Uterine Sarcoma Stage IIB Cervical Cancer Stage IIB Colon Cancer Stage IIB Gastric Cancer Stage IIB Ovarian Epithelial Cancer Stage IIB Ovarian Germ Cell Tumor Stage IIB Pancreatic Cancer Stage IIB Rectal Cancer Stage IIB Uterine Sarcoma Stage IIC Colon Cancer Stage IIC Ovarian Epithelial Cancer Stage IIC Ovarian Germ Cell Tumor Stage IIC Rectal Cancer Stage III Bladder Cancer Stage III Pancreatic Cancer Stage III Renal Cell Cancer Stage III Urethral Cancer Stage IIIA Cervical Cancer Stage IIIA Colon Cancer Stage IIIA Gastric Cancer Stage IIIA Ovarian Epithelial Cancer Stage IIIA Ovarian Germ Cell Tumor Stage IIIA Rectal Cancer Stage IIIA Uterine Sarcoma Stage IIIB Cervical Cancer Stage IIIB Colon Cancer Stage IIIB Gastric Cancer Stage IIIB Ovarian Epithelial Cancer Stage IIIB Ovarian Germ Cell Tumor Stage IIIB Rectal Cancer Stage IIIB Uterine Sarcoma Stage IIIC Colon Cancer Stage IIIC Gastric Cancer Stage IIIC Ovarian Epithelial Cancer Stage IIIC Ovarian Germ Cell Tumor Stage IIIC Rectal Cancer Stage IIIC Uterine Sarcoma Stage IV Bladder Cancer Stage IV Gastric Cancer Stage IV Ovarian Epithelial Cancer Stage IV Ovarian Germ Cell Tumor Stage IV Pancreatic Cancer Stage IV Renal Cell Cancer Stage IV Urethral Cancer Stage IVA Cervical Cancer Stage IVA Colon Cancer Stage IVA Rectal Cancer Stage IVA Uterine Sarcoma Stage IVB Cervical Cancer Stage IVB Colon Cancer Stage IVB Rectal Cancer Stage IVB Uterine Sarcoma Ureter Cancer Stage IIA Lung Carcinoma Stage IIB Lung Carcinoma Stage IIIA Lung Carcinoma Stage IIIB Lung Carcinoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

SINGLE

Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Arm I (FCPCI)

Participants receive FCPCI with an APN, comprising 4 home education sessions once weekly followed by 4 telephone support sessions for 30 minutes once monthly and 24 hour telephone support available for 6 months.

Group Type EXPERIMENTAL

educational intervention

Intervention Type OTHER

Receive FCPCI home education sessions

telephone-based intervention

Intervention Type BEHAVIORAL

Receive FCPCI telephone support sessions and 24 hour telephone support

quality-of-life assessment

Intervention Type PROCEDURE

Ancillary studies

questionnaire administration

Intervention Type OTHER

Ancillary studies

Arm II (usual care)

Participants receive usual care.

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

educational intervention

Receive FCPCI home education sessions

Intervention Type OTHER

telephone-based intervention

Receive FCPCI telephone support sessions and 24 hour telephone support

Intervention Type BEHAVIORAL

quality-of-life assessment

Ancillary studies

Intervention Type PROCEDURE

questionnaire administration

Ancillary studies

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

intervention, educational quality of life assessment

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Primary family caregivers of cancer patients with gastrointestinal (colorectal, pancreatic, gastric), gynecologic, urinary or lung cancers who are entering the City of Hope for treatment or follow-up
* Primary family caregivers of cancer patients who are diagnosed with stage II-IV disease
* Primary family caregivers of cancer patients with \> 6 months prognosis
* Living within a 50 mile radius of the City of Hope
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

National Cancer Institute (NCI)

NIH

Sponsor Role collaborator

American Cancer Society (ACS) National Office

UNKNOWN

Sponsor Role collaborator

City of Hope Medical Center

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Betty Ferrell

Role: PRINCIPAL_INVESTIGATOR

City of Hope Medical Center

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

City of Hope Medical Center

Duarte, California, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

NCI-2013-00839

Identifier Type: REGISTRY

Identifier Source: secondary_id

08176

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.